Figure 6.

Measurement of 19 kDa C-terminus of merozoite surface protein 1 (MSP1₁₉)-specific peripheral antigen-secreting cells (ASC) after vaccination and controlled human malaria infection (CHMI). (a) 19 kDa C-terminus of merozoite surface protein 1 (MSP1₁₉)-specific ASC responses (per million peripheral blood mononuclear cells (PBMC) were assessed by ex vivo ELISPOT at the stated time-points after MVA-MSP1 booster vaccination. Volunteers all received MVA-MSP1 booster vaccination either alone (n = 9) or co-administered with another MVA (n = 18). The responses are reported as the exact number of days following booster vaccination. (b) MSP1₁₉-specific ASC were also measured before (dC−1) and after CHMI at dC+7, dC+11 and dC+35. All volunteers (n = 9) received MVA-MSP1 booster vaccination only and were assayed exactly 7 days later for the d63 time-point [shown as day 7 in (a)]. Eight out of nine volunteers underwent CHMI of which 4/8 progressed to dC+11 before diagnosis. Data are presented as dot plots showing individual and median responses.